Tyra Biosciences Inc
NASDAQ:TYRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Beammwave AB
STO:BEAMMW B
|
SE |
Tyra Biosciences Inc
Free Cash Flow
Tyra Biosciences Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
Free Cash Flow
-$95.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$8.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
Tyra Biosciences Inc
Glance View
Tyra Biosciences, Inc. develops therapies for oncology and cancer diseases. The company is headquartered in Carlsbad, California and currently employs 25 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The firm uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The firm is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.
See Also
What is Tyra Biosciences Inc's Free Cash Flow?
Free Cash Flow
-95.3m
USD
Based on the financial report for Dec 31, 2025, Tyra Biosciences Inc's Free Cash Flow amounts to -95.3m USD.
What is Tyra Biosciences Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-64%
Over the last year, the Free Cash Flow growth was -35%. The average annual Free Cash Flow growth rates for Tyra Biosciences Inc have been -23% over the past three years , -64% over the past five years .
